🔍

Veerhealth Care Ltd (511523)

📊 BSE: 511523 🏢 Pharmaceuticals 📢 Latest filing: 03 Oct 2026

Latest quarterly results (Q1 FY27)

In its latest reported quarter, Q1 FY27, Veerhealth Care's revenue was ₹24.9 Cr (+455.1% year on year, +48.7% on the previous quarter), and net profit ₹1.2 Cr (+411.1% year on year); the operating margin was 7.7%.

Q1 FY27 (₹ Cr)	Value	YoY vs Q1 FY26	QoQ
Revenue	₹24.9	+455.1%	+48.7%
Operating profit	₹1.9	from loss	+161.3%
Net profit	₹1.2	+411.1%	from loss
EPS (₹)	0.61	+408.3%	from loss
Operating margin	7.7%	—	—

Full quarterly financials → Results calendar →

📢 Recent Corporate Announcements

Veerhealth Care Bags Rs 4.55 Cr Skincare Supply Order from Domestic FMCG Major

🟢 POSITIVE ⭐ 7/10

OTHER 📅 03 Oct 2026, 12:51 PM

Veerhealth Care Ltd has secured an order worth Rs 454.68 Lakhs (approx. Rs 4.55 crore) for the supply of face care products from an unnamed leading domestic FMCG company. The order comes with a short execution timeline of 45 days. Relative to the company's TTM revenue of Rs 53 crore, this single order represents approximately 8.6%, offering immediate quarterly revenue visibility. The contract is non-related party and awarded on an arm's length basis.

Received skincare order worth Rs 454.68 Lakhs from a domestic FMCG firm
Order execution period is within 45 days
Scope involves supply of face care products
Non-related party transaction with no promoter interest

💡 Monitor whether the delivery is completed within the stated 45-day window and reflected in the upcoming Q3 FY27 financial results.

Veerhealth Care Schedules 34th AGM for Sept 23, 2026; Issues Annual Report & KYC Notice

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 31 Aug 2026, 09:10 PM

Veerhealth Care has announced that its 34th Annual General Meeting (AGM) will be conducted via Video Conferencing on Wednesday, September 23, 2026, at 16:00 IST. The company dispatched communications containing the web-link to the FY 2025-2026 Annual Report to shareholders without registered email addresses as of the August 21, 2026 cut-off date. The letter also reminds physical shareholders to update mandatory KYC and banking details per SEBI regulations.

34th Annual General Meeting scheduled for September 23, 2026, at 16:00 IST via VC/OAVM
Cut-off date for unregistered shareholder dispatch set as August 21, 2026
Annual Report FY25-26 made available online at company website
Physical security holders urged to complete mandatory KYC updates under SEBI circular dated May 7, 2024

💡 Shareholders holding physical shares should ensure their KYC and bank account details are updated with RTA Purva Sharegistry to receive future corporate disbursements.

Veerhealth Care Schedules 34th AGM on Sept 23, 2026; Issues FY26 Annual Report

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 31 Aug 2026, 09:06 PM

Veerhealth Care Ltd has scheduled its 34th Annual General Meeting (AGM) for September 23, 2026, via Video Conferencing. Alongside the notice, the company released its FY26 Annual Report detailing full-year net sales of Rs 32.48 Cr and net profit of Rs 54.40 lakh (Rs 0.54 Cr). Total debt as of March 31, 2026, was Rs 4.58 Cr, reflecting a debt-to-equity ratio of 0.20. The register of members will remain closed from September 17 to September 23, 2026, with the e-voting cut-off set for September 16, 2026.

34th AGM scheduled for September 23, 2026, at 11:30 AM via Video Conferencing
FY26 Net Sales stood at Rs 32.48 Cr and Net Profit at Rs 54.40 lakh
Total Debt stood at Rs 4.58 Cr against Net Worth/Equity of Rs 22.92 Cr (D/E of 0.20)
Book closure fixed from September 17, 2026 to September 23, 2026 (Cut-off date: September 16, 2026)

💡 Eligible shareholders as of September 16, 2026 can participate in remote e-voting; investors should monitor quarterly performance trends and export order traction noted in the annual report.

Veerhealth Care Files FY26 Annual Report; 34th AGM Scheduled for September 23, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 31 Aug 2026, 09:00 PM

Veerhealth Care Limited has submitted its Annual Report for FY 2025-26 along with the notice for its 34th Annual General Meeting, to be held via Video Conferencing on September 23, 2026. For FY26, the company reported net sales of ₹32.48 crore and a net profit of ₹0.54 crore. Total debt stood reduced at ₹4.58 crore compared to ₹4.91 crore in the previous fiscal year, with a debt-to-equity ratio of 0.20x. The company noted improvements in inventory turnover and operational efficiency following US FDA registration, driving bulk export orders.

34th AGM scheduled for September 23, 2026, with book closure from September 17 to September 23, 2026.
FY26 Net Sales stood at ₹32.48 crore with Net Profit at ₹54.40 lakh (₹0.54 crore).
Total debt as of March 31, 2026, stood at ₹4.58 crore against shareholders equity of ₹22.92 crore (D/E of 0.20x).
Current ratio was 1.37x as of March 31, 2026, compared to 2.43x in FY25 due to higher trade payables.

💡 Track voting outcomes from the AGM on September 23, 2026, and monitor subsequent quarterly operational performance regarding export volumes.

Veerhealth Care Q1 Revenue Surges 388% YoY to Rs 25.09 Cr; FY27 Target at Rs 105 Cr

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 17 Aug 2026, 08:55 AM

Veerhealth Care reported a 388.13% YoY surge in Q1FY27 total revenue to Rs 25.09 crore, with net profit rising 412.50% YoY to Rs 1.23 crore. The company highlighted major order wins in FY27, including Rs 32.93 crore from a New York-based firm and Rs 18.24 crore from a domestic FMCG firm. Management issued strong guidance targeting Rs 105 crore in total income with Rs 5-6 crore PAT for FY27, and Rs 156 crore total income for FY28. Growth is supported by a newly commenced manufacturing facility and USFDA plant clearance for OTC exports.

Q1FY27 total revenue rose 388.13% YoY to Rs 25.09 crore, with PAT up 412.50% YoY to Rs 1.23 crore.
EBITDA increased 233.87% YoY to Rs 2.07 crore, though EBITDA margin contracted 381 bps YoY to 8.25%.
Secured sizeable order wins in FY27, including Rs 32.93 crore from New York and Rs 18.24 crore from an Indian FMCG player.
Management guided FY27 revenue of Rs 105 crore (PAT Rs 5-6 crore) and FY28 revenue of Rs 156 crore (PAT Rs 9-10 crore).

💡 Track quarterly order fulfillment rates, margin expansion, and progress toward meeting the guided Rs 105 crore annual top-line target.

Veerhealth Care Q1 PAT Jumps to ₹1.23 Cr; Revenue Up 455% YoY; New CS Appointed

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 13 Aug 2026, 05:24 PM

Veerhealth Care reported a massive surge in Q1 FY27 (June 2026) revenue to ₹24.93 Cr, a 455% increase compared to ₹4.49 Cr in the same quarter last year. The company turned profitable with a net profit of ₹1.23 Cr, recovering from a loss of ₹0.35 Cr in the preceding March 2026 quarter. Additionally, the company has received ₹4.87 Cr as part payment for 1 crore warrants issued at ₹20.25 each. The board also appointed Ruchi Shah, daughter of the Chairperson, as the new Company Secretary following the resignation of Ashita Chittora.

Revenue from operations grew 455.7% YoY to ₹24.93 Cr in Q1 FY27.
Net profit stood at ₹1.23 Cr for the quarter, compared to ₹0.24 Cr in Q1 FY26.
Received ₹4.87 Cr towards 1,00,00,000 warrants convertible at ₹20.25 per share.
Basic EPS improved to ₹0.61 from ₹0.12 YoY and a negative ₹0.18 in the previous quarter.
New CS Ruchi Shah appointed, who is the daughter of Chairperson Mr. Yogesh Shah.

💡 Investors should monitor if the sharp revenue spike in Q1 (which represents ~77% of total FY26 revenue) is sustainable or due to a one-off bulk order. Watch for the full conversion of warrants and the resulting equity dilution.

Veerhealth Care Q1 Revenue Surges 455% to ₹24.93 Cr; Appoints New CS

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 13 Aug 2026, 05:23 PM

Veerhealth Care reported a massive scale-up in Q1 FY27, with revenue jumping to ₹24.93 Cr from ₹4.49 Cr in the same quarter last year. Net profit followed suit, rising to ₹1.23 Cr compared to ₹0.24 Cr YoY. The company also announced the appointment of Ms. Ruchi Shah as Company Secretary, noting she is the daughter of the Chairperson. Furthermore, the company has received ₹4.87 Cr as part-payment for a ₹20.25 Cr warrant issuance, indicating significant upcoming capital infusion.

Revenue from operations grew 455% YoY to ₹24.93 Cr for the quarter ended June 30, 2026
Net profit increased to ₹1.23 Cr in Q1 FY27 from ₹0.24 Cr in Q1 FY26
Received ₹4.87 Cr towards the issuance of 1,00,00,000 warrants priced at ₹20.25 each
Appointed Ms. Ruchi Shah as CS and Compliance Officer, effective August 13, 2026
Annual General Meeting (AGM) scheduled for September 23, 2026

💡 Investors should monitor if the sharp revenue jump in Q1 is sustainable or driven by one-off orders, and track the conversion of warrants which will lead to equity dilution.

₹24.93 Cr Revenue: Veerhealth Care Reports 455% YoY Growth in Q1 FY27

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 13 Aug 2026, 05:18 PM

Veerhealth Care reported a massive surge in Q1 FY27 revenue to ₹24.93 cr, a 455% increase from ₹4.49 cr in the same quarter last year. Net profit rose to ₹1.23 cr compared to ₹0.24 cr YoY, marking a sharp recovery from the ₹0.35 cr loss in the preceding March 2026 quarter. The company also confirmed receiving ₹4.87 cr as part payment for a ₹20.25 cr warrant issue. Additionally, the Board appointed Ruchi Shah, daughter of the Chairperson, as the new Company Secretary following the resignation of the incumbent.

Revenue from operations grew 455% YoY to ₹24.93 cr from ₹4.49 cr.
Net profit increased to ₹1.23 cr from ₹0.24 cr in the year-ago period.
Quarterly EPS improved to ₹0.61 from ₹0.12 in June 2025.
Received ₹4.87 cr towards the issuance of 1,00,00,000 warrants priced at ₹20.25 each.
Total expenses rose to ₹23.61 cr, largely driven by stock-in-trade purchases of ₹25.51 cr.

💡 Investors should monitor if this high revenue run-rate is sustainable or driven by one-off bulk orders, and track the conversion of warrants which will lead to equity dilution.

Veerhealth Care Q1 Revenue Jumps 455% to ₹24.93 Cr; PAT at ₹1.23 Cr

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 13 Aug 2026, 05:15 PM

Veerhealth Care reported a massive surge in Q1 FY27 performance, with revenue reaching ₹24.93 cr compared to ₹4.49 cr in Q1 FY26. Net profit for the quarter stood at ₹1.23 cr, a significant turnaround from the ₹0.35 cr loss in the preceding March quarter. The company also confirmed receiving ₹4.87 cr as part payment for 1 crore warrants issued at ₹20.25 each. Additionally, a new Company Secretary, who is a related party to the Chairperson, has been appointed.

Revenue from operations increased by 455% YoY to ₹24.93 cr in Q1 FY27.
Net profit rose to ₹1.23 cr in Q1 FY27 from ₹0.24 cr in the same quarter last year.
Basic EPS improved to ₹0.61 from ₹0.12 YoY.
Received ₹4.87 cr towards the issuance of 1,00,00,000 warrants priced at ₹20.25 each.
34th Annual General Meeting scheduled for September 23, 2026.

💡 Investors should monitor if this sharp revenue growth is sustainable across future quarters and track the utilization of the ₹20.25 cr warrant proceeds for business expansion.

₹5.27 Cr Repeat Order from Leading FMCG Group; FY27 Revenue Target Set at ₹105 Cr

🟢 POSITIVE ⭐ 7/10

EXPANSION 📅 05 Aug 2026, 04:51 PM

Veerhealth Care has secured a repeat monthly order worth ₹5.27 Crores from a prominent 125-year-old Indian FMCG group for face care products. This single order represents approximately 16.5% of the company's TTM revenue and is scheduled for execution within 45 days. Additionally, the company has entered the Sudan market with a ₹15.74 lakh sample order for Gripe Water. Management has issued aggressive guidance, targeting ₹105 Crores in revenue for FY27, which would be a 223% increase over FY26 revenue of ₹32.48 Crores.

Received a repeat monthly order worth ₹5.27 Crores for face care products from a major FMCG client.
Order execution timeline is set for within 45 days.
Management projects FY27 total income of ₹105 Crores with a PAT of ₹5-6 Crores.
Secured first export sample order from Sudan worth ₹15.74 lakhs.
Company is in advanced talks with a large Indo-Canadian hotel amenities supplier.

💡 Investors should monitor the quarterly revenue run-rate to see if it aligns with the ambitious ₹105 Cr annual target. Key execution milestones include the successful delivery of the current ₹5.27 Cr order and the conversion of 'advanced talks' with the hotel amenities supplier into firm contracts.

Veerhealth Care Board Meeting on August 13 to Approve Q1 FY27 Results

🟡 NEUTRAL ⭐ 3/10

BOARD_MEETING 📅 05 Aug 2026, 04:16 PM

Veerhealth Care Ltd has scheduled a board meeting for August 13, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026. Additionally, the board will approve the Director's Report for the financial year ended March 31, 2026, and finalize the notice for the 34th Annual General Meeting. This follows a fiscal year (FY26) where revenue grew 95% to ₹32.48 cr, though the company reported a net loss of ₹0.35 cr in the most recent March 2026 quarter. The trading window for insiders will reopen on August 16, 2026.

Board meeting scheduled for August 13, 2026, to approve Q1 FY27 results.
Trading window for securities to reopen on August 16, 2026.
Board to approve the draft notice for the 34th Annual General Meeting.
Meeting will also finalize the Director's Report for the financial year ending March 31, 2026.

💡 Investors should monitor the results on August 13 to see if the company can sustain the revenue growth seen in FY26 while improving margins, following the loss reported in the previous quarter.

₹5.27 Cr Skincare Order from Large FMCG Company to be Executed in 45 Days

🟢 POSITIVE ⭐ 7/10

OTHER 📅 04 Aug 2026, 05:27 PM

Veerhealth Care has secured a domestic order worth ₹526.84 Lakhs (₹5.27 Cr) for the supply of face care products to a major Indian FMCG company. This single order is highly material, representing approximately 16.5% of the company's total FY26 revenue of ₹32.48 Cr. The contract requires rapid execution within a 45-day window, which is expected to significantly impact the immediate quarterly turnover. While the client's identity is withheld due to confidentiality, the scale of the win is substantial for a micro-cap company with an ₹84 Cr market valuation.

Received a domestic order valued at ₹526.84 Lakhs for skincare products.
Order execution timeline is strictly set at 45 days.
Order value represents ~16.5% of the company's TTM revenue of ₹32 Cr.
Contract awarded by one of India's largest FMCG companies (name withheld).
Focus of the order is specifically on the supply of Face Care Products.

💡 Investors should monitor the September 2026 quarterly results to verify the successful execution of this order and its impact on operating margins, which stood at 7.6% in FY26.

Rs 15.74 Lakh Export Order from Sudan for Veerhealth Care Ltd

🟡 NEUTRAL ⭐ 3/10

EXPANSION 📅 24 Jul 2026, 04:29 PM

Veerhealth Care has secured its first export order from Sudan for the supply of Gripe Water, valued at Rs. 15.74 lakhs. While the order size is small, representing approximately 0.49% of the company's TTM revenue of Rs. 32 Cr, it marks a strategic entry into the African pediatric care market. The contract is scheduled for execution within a 45-day timeline. This development follows a period of high stock price volatility, with the company reporting a net loss of Rs. 0.35 Cr in the most recent quarter (Mar 2026).

Secured export order valued at Rs. 15,73,992 for Gripe Water supply
Execution timeline mandated within 45 days from the order date
Marks the company's first strategic entry into the Sudan market
Order value represents ~0.49% of TTM revenue (Rs. 32 Cr)
Targeting expansion in the pediatric and wellness care segment in Africa

💡 Investors should monitor if this initial entry leads to larger, recurring orders from the African region in future quarterly filings to determine if the export strategy is scaling.

Rs 76.40 Lakh Sample Order from Leading FMCG Group for Skincare Products

🟢 POSITIVE ⭐ 6/10

EXPANSION 📅 23 Jul 2026, 04:38 PM

Veerhealth Care has secured a sample order worth Rs 76.40 lakhs from a prominent 125-year-old Indian FMCG group for skincare products. While the order is small at approximately 2.4% of TTM revenue, it is strategically significant as it involves a new MRP structure for brand promotion and market expansion. The company has also issued aggressive forward guidance, targeting a revenue of Rs 105 crore in FY27, which is more than 3x its current TTM revenue of Rs 32 crore. Execution of this specific order is expected within 45 days.

Received a new sample order worth Rs 76.40 lakhs for skincare products from a leading FMCG company.
Order execution timeline set for 45 days from the date of receipt.
Company projected FY27 total income of Rs 105 crore with a minimum PAT of Rs 5-6 crore.
Company projected FY28 total income of Rs 156 crore with a minimum PAT of Rs 9-10 crore.
Reported book value per share for FY26 at Rs 11.46, expected to increase with preferential warrant funds.

💡 Investors should monitor the conversion of this sample order into larger recurring contracts and track quarterly revenue growth against the company's ambitious FY27 target of Rs 105 crore.

Rs 76.40 Lakh Order Win for Skincare Products from Leading FMCG Company

🟢 POSITIVE ⭐ 5/10

ROUTINE 📅 22 Jul 2026, 05:16 PM

Veerhealth Care has secured a contract manufacturing order worth Rs 76.40 lakhs from a leading domestic FMCG company for skincare products. The order is expected to be executed within a short timeframe of 45 days, contributing to the current quarter's revenue. While the order size is relatively small at approximately 2.4% of the company's TTM revenue of Rs 32 crore, it validates the company's manufacturing capabilities for major brands. The products are intended for a new brand promotion and market expansion initiative by the client.

Order value of Rs 76.40 lakhs for skincare manufacturing
Strict execution timeline of 45 days from the date of the order
Order represents approximately 2.4% of the TTM revenue of Rs 32 crore
Client is a leading domestic FMCG company (name withheld due to confidentiality)

💡 Watch for the successful execution of this order within the 45-day window and whether it leads to repeat or larger-scale orders from the same FMCG client in future quarters.

View All 511523 Announcements on Live Market Tracking →